Search

everythinglearnresearchcommunity

for

Search:↓

Certain chemicals and peptides can promote hair growth or prevent baldness.

Finasteride, when given in high oral doses to pregnant monkeys, caused genital abnormalities in male fetuses, but not in female fetuses or those exposed to intravenous finasteride.

Most care for benign prostatic hyperplasia follows guidelines, but 5-α reductase inhibitors are often used incorrectly.

New understanding and treatments for hair loss are improving, but more research is needed.

Men with male pattern baldness may not have different hormone levels, but their hair follicles are likely more sensitive to hormones.

New liposome treatment successfully delivers CRISPR to deactivate a key enzyme in androgen-related disorders.

Finasteride reduces blood loss and the need for blood transfusions during and after TURP surgery.

The new progesterone derivatives effectively inhibit 5α-reductase and bind to the androgen receptor.

Dutasteride can stabilize hair loss in patients with frontal fibrosing alopecia, but its safety in women is unclear, so use it with caution.

5-α reductase inhibitors do not significantly affect male reproductive function but may reduce semen volume.

5-alpha-reductase inhibitors may reduce COVID-19 symptoms in bald males.

Dutasteride is the most effective hair loss treatment after 24 weeks, but finasteride leads to the most hair growth after 48 weeks.

Finasteride harms Daphnia magna's reproduction, growth, and metabolism.

Dutasteride is safe and effective for treating hair loss, but may decrease libido.

Dutasteride is more effective than finasteride at increasing hair count and reversing hair thinning in men with hair loss, but both have similar side effects.

5-alpha reductase inhibitors can cause sexual, neurologic, endocrine, and cardiovascular side effects, but these are rare and usually stop after ending treatment.

The document concludes that women should not use 5-alpha-reductase inhibitors due to the risk of birth defects and limited effectiveness.

The review found that women using hair loss drugs like finasteride and dutasteride rarely reported sexual side effects.

The document concluded that more research is needed to find the best treatment for Frontal fibrosing alopecia.

The document concludes that sexual and psychiatric side effects from 5-alpha-reductase inhibitors are reported, but more high-quality research is needed to understand how often they occur.

Finasteride effectively treats male hair loss, increasing length and thickness.

5-alpha reductase inhibitors slightly increase the risk of sexual and mood side effects, and breast growth in men.

5-alpha reductase inhibitors can cause sexual side effects like erectile dysfunction and reduced sexual desire, sometimes lasting after stopping the drug.

S5αR inhibitors might help treat schizophrenia and other mental disorders but need more research.

5 alpha reductase inhibitors can cause sexual, cognitive, and muscle side effects, and may slightly increase aggressive cancer risk.

Frontal Fibrosing Alopecia's cause is unclear, affects mainly postmenopausal women, and current treatments focus on stopping hair loss rather than regrowth.

Early diagnosis and combination therapy, especially with finasteride and dutasteride, are key to managing Frontal Fibrosing Alopecia effectively.

Hormones like androgens, estrogen, thyroid hormones, and stress hormones can contribute to hair loss, and treatments target these hormonal imbalances.

Nanocarrier-based treatments show promise for better hair growth in androgenetic alopecia but need more research.

Hormonal therapies help treat female hair loss, but results are slow and vary.